Molecular basis of arterial stiffening: Role of glycation-a mini-review

Gerontology

Volumn 58, Issue 3, 2012, Pages 227-237

  Sell, David R ^a   Monnier, Vincent M ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Advanced glycation; Aging; Collagen; Diabetes; Elastin; Intervention; Oxidation

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; CARBONYL DERIVATIVE; COLLAGEN; ELASTIN; GLUCOSE; GLYCERYL TRINITRATE; GLYOXAL; METAL; PENTOSIDINE; PROTEIN;

AGED; AGING; ARTERIAL STIFFNESS; ARTERY WALL; ATHEROSCLEROSIS; AUTOFLUORESCENCE; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CROSS LINKING; DIABETES MELLITUS; DIET RESTRICTION; DRUG EFFECT; ELASTIC FIBER; ENDOTHELIAL PROGENITOR CELL; EXERCISE; EXTRACELLULAR MATRIX; GLUCOSE BLOOD LEVEL; GLYCATION; HUMAN; HYPERTENSION; LIPID PEROXIDATION; NONHUMAN; OXIDATION; PRIORITY JOURNAL; REVIEW; SKIN; STEM CELL; STREPTOZOCIN DIABETES; VASCULAR SMOOTH MUSCLE;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; COLLAGEN; DIABETES MELLITUS; DISEASE PROGRESSION; ELASTIN; FEMALE; GERIATRIC ASSESSMENT; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERTENSION; MALE; MOLECULAR BIOLOGY; PROGNOSIS; RISK ASSESSMENT; VASCULAR STIFFNESS;

EID: 84860348119     PISSN: 0304324X     EISSN: 14230003     Source Type: Journal    
DOI: 10.1159/000334668     Document Type: Review

References (75)

1. Adji A, O'Rourke MF, Namasivayam M: Arterial stiffness, its assessment, prognostic value, and implications for treatment. Am J Hypertens 2011; 24: 5-17.
2. Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9. (Pubitemid 29019345)
3. Cattan V, Kakou A, Louis H, Lacolley P: Pathophysiology, genetic, and therapy of arterial stiffness. Biomed Mater Eng 2006; 16(suppl) : S155-S161. (Pubitemid 43953685)
4. Powell JT, Vine N, Crossman M: On the accumulation of D-aspartate in elastin and other proteins of the ageing aorta. Atherosclerosis 1992; 97: 201-208.
5. Reiser KM, Amigable MA, Last JA: Nonenzymatic glycation of type I collagen: the effects of aging on preferential glycation sites. J Biol Chem 1992; 267: 24207-24216.
6. Dai Z, Wang B, Sun G, Fan X, Anderson VE, Monnier VM: Identification of glucose-derived cross-linking sites in ribonuclease A. J Proteome Res 2008; 7: 2756-2768.
7. Rabbani N, Thornalley PJ: Glycation research in amino acids: a place to call home. Amino Acids 2010;DOI 10.1007/s00726-010-0782-1.
8. Lyons TJ, Jenkins AJ: Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis. Diabetes Rev 1997; 5: 365-391. (Pubitemid 28033523)
9. Peppa M, Uribarri J, Vlassara H: The role of advanced glycation end products in the development of atherosclerosis. Curr Diab Rep 2004; 4: 31-36. (Pubitemid 39359508)
10. Tohno Y, Tohno S, Mahakkanukrauh P, Azuma C, Moriwake Y, Ongkana N, Kumai T, Minami T, Maruyama H: Earlier accumulation of calcium, phosphorus, and magnesium in the coronary artery in comparison with the ascending aorta, aortic valve, and mitral valve. Biol Trace Elem Res 2006; 112: 31-42. (Pubitemid 44337203)
11. Zhang A, Park SK, Wright RO, Weisskopf MG, Mukherjee B, Nie H, Sparrow D, Hu H: HFE H63D polymorphism as a modifier of the effect of cumulative lead exposure on pulse pressure: the Normative Aging Study. Environ Health Perspect 2010; 118: 1261-1266.
12. Sell DR, Strauch CM, Shen W, Monnier VM: 2-Aminoadipic acid is a marker of protein carbonyl oxidation in the aging human skin: effects of diabetes, renal failure and sepsis. Biochem J 2007; 404: 269-277. (Pubitemid 46849598)
13. Scott JE: Elasticity in extracellular matrix 'shape modules' of tendon, cartilage, etc.: a sliding proteoglycan-filament model. J Physiol 2003; 553(Pt 2) : 335-343. (Pubitemid 37527538)
14. Fonck E, Feigl GG, Fasel J, Sage D, Unser M, Rüfenacht DA, Stergiopulos N: Effect of aging on elastin functionality in human cerebral arteries. Stroke 2009; 40: 2552-2556.
15. Greenwald SE: Ageing of the conduit arteries. J Pathol 2007; 211: 157-172. (Pubitemid 46195514)
16. Winlove CP, Parker KH, Avery NC, Bailey AJ: Interactions of elastin and aorta with sugars in vitro and their effects on biochemical and physical properties. Diabetologia 1996; 39: 1131-1139. (Pubitemid 26319935)
17. Saxena AK, Saxena P, Wu X, Obrenovich M, Weiss MF, Monnier VM: Protein aging by carboxymethylation of lysines generates sites for divalent metal and redox active copper binding: relevance to diseases of glycoxidative stress. Biochem Biophys Res Commun 1999; 260: 332-338. (Pubitemid 29352066)
18. Mizutari K, Ono T, Ikeda K, Kayashima K, Horiuchi S: Photo-enhanced modification of human skin elastin in actinic elastosis by N(epsilon)- (carboxymethyl)lysine, one of the glycoxidation products of the Maillard reaction. J Invest Dermatol 1997; 1997: 797-802. (Pubitemid 27192356)
19. Qian M, Liu M, Eaton JW: Transition metals bind to glycated proteins forming redox active 'glycochelates': implications for the pathogenesis of certain diabetic complications. Biochem Biophys Res Commun 1998; 250: 385-389. (Pubitemid 28463887)
20. Sims TJ, Rasmussen LM, Oxlund H, Bailey AJ: The role of glycation crosslinks in diabetic vascular stiffening. Diabetologia 1996; 39: 946-951. (Pubitemid 26249114)
21. Shoda H, Miyata S, Liu BF, Yamada H, Ohara T, Suzuki K, Oimomi M, Kasuga M: Inhibitory effects of tenilsetam on the Maillard reaction. Endocrinology 1997; 138: 1886-1892. (Pubitemid 27180803)
22. Sakata N, Noma A, Yamamoto Y, Okamoto K, Meng J, Takebayashi S, Nagai R, Horiuchi S: Modification of elastin by pentosidine is associated with the calcification of aortic media in patients with end-stage renal disease. Nephrol Dial Transplant 2003; 18: 1601-1609. (Pubitemid 36939635)
23. Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R, Horiuchi S: Increased advanced glycation end products in atherosclerotic lesions of patients with endstage renal disease. Atherosclerosis 1999; 142: 67-77. (Pubitemid 28551811)
24. Xue M, Rabbani N, Thornalley PJ: Glyoxalase in ageing. Semin Cell Dev Biol 2011; 22: 293-301.
25. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820. (Pubitemid 34000785)
26. Engelen L, Ferreira I, Brouwers O, Henry RM, Dekker JM, Nijpels G, Heine RJ, van Greevenbroek MM, van der Kallen CJ, Blaak EE, Feskens EJ, ten Cate H, Stehouwer CD, Schalkwijk CG: Polymorphisms in glyoxalase 1. gene are not associated with vascular complications: the Hoorn and CoDAM studies. J Hypertens 2009; 27: 1399-1403.
27. Negre-Salvayre A, Salvayre R, Augé N, Pamplona R, Portero-Otín M: Hyperglycemia and glycation in diabetic complications. Antioxid Redox Signal 2009; 11: 3071-3109.
28. Jandeleit-Dahm K, Cooper ME: The role of AGEs in cardiovascular disease. Curr Pharm Des 2008; 14: 979-986. (Pubitemid 351753286)
29. Choi KM, Yoo HJ, Kim HY, Lee KW, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH: Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. Int J Cardiol 2009; 132: 96-101.
30. Thornalley PJ, Rabbani N: Highlights and hotspots of protein glycation in end-stage renal disease. Semin Dial 2009; 22: 400-404.
31. Ueno H, Koyama H, Tanaka S, Fukumoto S, Shinohara K, Shoji T, Emoto M, Tahara H, Kakiya R, Tabata T, Miyata T, Nishizawa Y: Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. Metabolism 2008; 57: 1452-1457.
32. Monnier VM, Sell DR, Genuth S: Glycation products as markers and predictors of the progression of diabetic complications. Ann NY Acad Sci 2005; 1043: 567-581. (Pubitemid 41123947)
33. Baumann M, Richart T, Sollinger D, Pelisek J, Roos M, Kouznetsova T, Eckstein HH, Heemann U, Staessen JA: Association between carotid diameter and the advanced glycation end product N-epsilon-carboxymethyllysine (CML). Cardiovasc Diabetol 2009; 8: 45.
34. Kanauchi M, Tsujimoto N, Hashimoto T: Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care 2001; 24: 1620-1623. (Pubitemid 33716459)
35. Suliman ME, Stenvinkel P, Jogestrand T, Maruyama Y, Qureshi AR, Bárány P, Heimbürger O, Lindholm B: Plasma pentosidine and total homocysteine levels in relation to change in common carotid intima-media area in the first year of dialysis therapy. Clin Nephrol 2006; 66: 418-425. (Pubitemid 44896150)
36. Basta G, Castagnini M, Del Turco S, Epistolato MC, Righini P, Sangiorgi GM, De Caterina R, Tanganelli P: High plasma levels of the soluble receptor for advanced glycation endproducts in patients with symptomatic carotid atherosclerosis. Eur J Clin Invest 2009; 39: 1065-1072.
37. Yokota C, Minematsu K, Tomii Y, Naganuma M, Ito A, Nagasawa H, Yamaguchi T: Low levels of plasma soluble receptor for advanced glycation end products are associated with severe leukoaraiosis in acute stroke patients. J Neurol Sci 2009; 287: 41-44.
38. Sell DR, Lane MA, Obrenovich ME, Mattison JA, Handy A, Ingram DK, Cutler RG, Roth GS, Monnier VM: The effect of caloric restriction on glycation and glycoxidation in skin collagen of nonhuman primates. J Gerontol Biol Sci 2003; 58A : 508-516. (Pubitemid 36702687)
39. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, Cleary PA, Lachiin J, Genuth S: Skin collagen glycation, glycoxidation and crosslinking are lower in subjects with long-term intensive vs. conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA 1 C as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999; 48: 870-880. (Pubitemid 29153089)
40. Sikka G, Yang R, Reid S, Benjo A, Koitabashi N, Camara A, Baraban E, O'Donnell CP, Berkowitz DE, Barouch LA: Leptin is essential in maintaining normal vascular compliance independent of body weight. Int J Obes (Lond) 2010; 34: 203-206.
41. Miyaki A, Maeda S, Yoshizawa M, Misono M, Saito Y, Sasai H, Endo T, Nakata Y, Tanaka K, Ajisaka R: Effect of weight reduction with dietary intervention on arterial distensibility and endothelial function in obese men. Angiology 2009; 60: 351-357.
42. Tanaka H, Dinenno FA, Monahan KD, Clevenger CM, DeSouza CA, Seals DR: Aging, habitual exercise, and dynamic arterial compliance. Circulation 2000; 102: 1270-1275.
43. Nosaka T, Tanaka H, Watanabe I, Sato M, Matsuda M: Influence of regular exercise on age-related changes in arterial elasticity: mechanistic insights from wall compositions in rat aorta. Can J Appl Physiol 2003; 28: 204-212. (Pubitemid 37033785)
44. Avery NC, Bailey AJ: Enzymatic and nonenzymatic cross-linking mechanisms in relation to turnover of collagen: relevance to aging and exercise. Scand J Med Sci Sports 2005; 15: 231-240. (Pubitemid 41032387)
45. Momma H, Niu K, Kobayashi Y, Guan L, Sato M, Guo H, Chujo M, Otomo A, Yufei C, Tadaura H, Saito T, Mori T, Miyata T, Nagatomi R: Skin advanced glycation end product accumulation and muscle strength among adult men. Eur J Appl Physiol 2011; 111: 1545-1552.
46. Boor P, Celec P, Behuliak M, Grancic P, Kebis A, Kukan M, Pronayová N, Liptaj T, Ostendorf T, Sebeková K: Regular moderate exercise reduces advanced glycation and ameliorates early diabetic nephropathy in obese Zucker rats. Metabolism 2009; 58: 1669-1677.
47. Choi SY, Chang HJ, Choi SI, Kim KI, Cho YS, Youn TJ, Chung WY, Chae IH, Choi DJ, Kim HS, Kim CH, Oh BH, Kim MH: Long-term exercise training attenuates age-related diastolic dysfunction: association of myocardial collagen cross-linking. J Korean Med Sci 2009; 24: 32-39.
48. Monnier VM, Sell DR: Prevention and repair of protein damage by the Maillard reaction in vivo. Rejuvenation Res 2006; 9: 264-273. (Pubitemid 43856818)
49. Collard F, Zhang J, Nemet I, Qanungo KR, Monnier VM, Yee VC: Crystal structure of the deglycating enzyme fructosamine oxidase (Amadoriase II). J Biol Chem 2008; 283: 27007-27016.
50. Semba RD, Nicklett EJ, Ferrucci L: Does accumulation of advanced glycation end products contribute to the aging phenotype? J Gerontol A Biol Sci Med Sci 2010; 65: 963-975.
51. Agalou S, Ahmed N, Thornalley PJ, Dawnay A: Advanced glycation end product free adducts are cleared by dialysis. Ann NY Acad Sci 2005; 1043: 734-739. (Pubitemid 41123967)
52. Li YM, Mitsuhashi T, Wojciechowicz D, Shimizu N, Li J, Stitt A, He C, Banerjee D, Vlassara H: Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci USA 1996; 93: 11047-11052. (Pubitemid 26333115)
53. Tesch GH, Lim KH: Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy. Am J Physiol Renal Physiol 2011; 300 : F301-F310.
54. Furber JD: Extracellular glycation crosslinks: prospects for removal. Rejuvenation Res 2006; 9: 274-278. (Pubitemid 43856819)
55. Loomans CJ, Dao HH, van Zonneveld AJ, Rabelink TJ: Is endothelial progenitor cell dysfunction involved in altered angiogenic processes in patients with hypertension? Curr Hypertens Rep 2004; 6: 51-54. (Pubitemid 39359542)
56. Thomas MC, Baynes JW, Thorpe SR, Cooper ME: The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets 2005; 6: 453-474. (Pubitemid 40916272)
57. Wu MS, Liang JT, Lin YD, Wu ET, Tseng YZ, Chang KC: Aminoguanidine prevents the impairment of cardiac pumping mechanics in rats with streptozotocin and nicotinamide-induced type 2 diabetes. Br J Pharmacol 2008; 154: 758-764.
58. Chang KC, Tseng CD, Wu MS, Liang JT, Tsai MS, Cho YL, Tseng YZ: Aminoguanidine prevents arterial stiffening in a new rat model of type 2 diabetes. Eur J Clin Invest 2006; 36: 528-535.
59. Brownlee M, Vlassara H, Kooney T, Ulrich P, Cerami A: Aminoguanidine prevents diabetes-induced arterial wall protein crosslinking. Science 1986; 232: 1629-1632. (Pubitemid 16095602)
60. Chan V, Hoey A, Brown L: Improved cardiovascular function with aminoguanidine in DOCA-salt hypertensive rats. Brit J Pharmacol 2006; 148: 902-908. (Pubitemid 44543607)
61. Cantini C, Kieffer P, Corman B, Liminana P, Atkinson J, Lartaud-Idjouadiene I: Aminoguanidine and aortic wall mechanics, structure, and composition in aged rats. Hypertens 2001; 38: 943-948. (Pubitemid 34258698)
62. Montagnani M: Diabetic cardiomyopathy: how much does it depend on AGE? Br J Pharmacol 2008; 154: 725-726. (Pubitemid 351821582)
63. Price DL, Rhett PM, Thorpe SR, Baynes JW: Chelating activity of advanced glycation end-product (AGE) inhibitors. J Biol Chem 2001; 276: 48967-48972.
64. Zheng Y, Li XK, Wang Y, Cai L: The role of zinc, copper and iron in the pathogenesis of diabetes and diabetic complications: therapeutic effects by chelators. Hemoglobin 2008; 32: 135-145. (Pubitemid 351264519)
65. Sell DR, Nelson JF, Monnier VM: Effect of chronic aminoguanidine treatment on agerelated glycation, glycoxidation, and collagen cross-linking in the Fischer 344 rat. J Gerontol Biol Sci 2001; 56A : B405-B411. (Pubitemid 32816731)
66. Vasan S, Foiles P, Founds H: Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys 2003; 419: 89-96. (Pubitemid 37272162)
67. Thornalley PJ, Minhas HS: Rapid hydrolysis and slow alpha,beta-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links. Biochem Pharmacol 1999; 57: 303-307. (Pubitemid 29056208)
68. Yang S, Litchfield JE, Baynes JW: AGEbreakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats. Arch Biochem Biophys 2003; 412: 42-46. (Pubitemid 36324363)
69. Cerami A, Ulrich P: Pharmaceutical intervention of advanced glycation compounds. Novartis Found Symp 2001; 235: 202-216. (Pubitemid 33610143)
70. Biemel KM, Lederer MO: Site-specific quantitative evaluation of the protein glycation product N6-(2,3-dihydroxy-5,6-dioxohexyl)-L-lysinate by LC-(ESI)MS peptide mapping: evidence for its key role in AGE formation. Bioconjug Chem 2003; 14: 619-628. (Pubitemid 36597374)
71. Mentink CJ, Hendriks M, Levels AA, Wolffenbuttel BH: Glucose-mediated crosslinking of collagen in rat tendon and skin. Clin Chim Acta 2002: 69-76. (Pubitemid 34597055)
72. Rahbar S, Figarola JL: Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 2003; 419: 63-79. (Pubitemid 37287559)
73. Akagawa M, Sasaki T, Suyama K: Oxidative deamination of lysine residue in plasma protein of diabetic rats. Eur J Biochem 2002; 269: 5451-5458.
74. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ: Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003; 52: 2110-2120. (Pubitemid 36919806)
75. Hartog JW, Willemsen S, van Veldhuisen DJ, Posma JL, van Wijk LM, Hummel YM, Hillege HL, Voors AA, BENEFICIAL investigators: Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Heart Fail 2011; 13: 899-908.